Drugs designed to mimic exercise by blocking myostatin or activating FGF21 and GDF15 can increase muscle mass in some trials, but this doesn’t consistently improve strength, metabolism, or overall health, suggesting muscle size alone isn’t enough.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether pharmacological modulation of myostatin, FGF21, or GDF15 improves functional outcomes (strength, mobility) and metabolic health (insulin sensitivity, liver fat) more than placebo in adults with muscle-wasting or metabolic disease.
A systematic review and meta-analysis of all published RCTs testing myostatin inhibitors (e.g., bimagrumab), FGF21 analogues (e.g., pegozafermin), or GDF15 modulators in adults with sarcopenia, obesity, or NAFLD, with primary outcomes including 1RM strength, 6-minute walk distance, HOMA-IR, and liver fat by MRI, across at least 12 weeks of treatment.
Whether adding a myostatin inhibitor to resistance training improves strength more than training alone in older adults.
A double-blind RCT of 120 adults aged 65–75 with low muscle mass, randomized to 24 weeks of resistance training plus bimagrumab (10 mg/kg biweekly) or placebo, measuring changes in leg press 1RM, gait speed, and insulin sensitivity via clamp as primary endpoints.
Whether baseline FGF21 levels predict response to FGF21 analogue therapy in patients with NAFLD.
A prospective cohort of 200 adults with biopsy-proven NAFLD enrolled in a clinical trial of pegozafermin, measuring baseline serum FGF21 and liver fat by MRI, and tracking changes in fibrosis, insulin sensitivity, and weight over 48 weeks to determine if baseline levels predict response.
Whether responders to myostatin inhibition have distinct muscle gene expression profiles compared to non-responders.
A case-control study comparing muscle biopsy transcriptomes from 20 responders (≥10% lean mass gain) and 20 non-responders (≤2% gain) to bimagrumab treatment in sarcopenic adults, with pathway analysis focused on mTOR, ubiquitin-proteasome, and mitochondrial genes.
Whether circulating myostatin or FGF21 levels correlate with muscle strength and metabolic health in older adults.
A cross-sectional analysis of 400 adults aged 60–80 measuring serum myostatin, FGF21, and GDF15 alongside grip strength, 4-meter gait speed, HOMA-IR, and liver fat by MRI, adjusting for fat mass and physical activity.